Ravenquest Provides Update on Recent License and Production Capacity Expansion
10 Abril 2019 - 7:00AM
RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt:
1IT) (the “
Company” or
“
RavenQuest”) a federally licensed producer of
cannabis, is pleased to provide an update following receipt of its
cultivation license at its Edmonton facility and the capacity
expansion that comes with it.
Licensing of the Edmonton facility represents an
inflection point for the Company, increasing its licensed annual
cannabis production capacity to 11,000 kg—a 275% increase.
RavenQuest currently has a supply agreement with
Wayland Group, whereby RavenQuest has agreed to supply them with up
to 8,000 kg of cannabis in 2019. RavenQuest has also entered a
memorandum of understanding with the British Columbia Liquor
Distribution Branch (“BCLDB”) and expects to enter into an
agreement in to sell the remainder of its cannabis production to
them in 2019.
With respect to ramping up production at the
newly licensed Edmonton facility, RavenQuest CEO, George Robinson
stated “we have an experienced team in place at both Edmonton and
Markham facilities to ensure starting material is expedited safely
from the Markham facility to the Edmonton facility. Our experience
in cannabis consulting, together with the seasoned plant expertise
of Dr. Simerjeet Kaur and her team will enable us to bring
production online in Edmonton properly and at a rapid pace”.
“With the Edmonton facility online, RavenQuest
is on track to fulfill its supply agreement with the Wayland Group
and expects to be in a position to supply the BCLDB with cannabis
once a definitive supply agreement is reached” Robinson
continued.
In addition to an increase in cannabis revenue
for 2019, RavenQuest also anticipates a record year for its
Services Division, with several new clients signing contracts
including, notably, a one year agreement with Bonify valued at $1.5
million.
Once legalized, RavenQuest intends to deliver on
its broader growth strategy to provide value-added products across
a wide spectrum of delivery options including vaporization, edibles
and beverages. “Our plans include a diversified product offering of
unique experiences for cannabis consumers. These products will
differ substantially from the fractional distillates planned by our
competitors. Instead, we will place the emphasis on the full plant
extract, with the myriad flavours and profiles that come with
passing through the full plant experience to value added products”
stated Robinson.
“As we move past the licensing phase,” stated
Robinson, “2019 promises to be an unprecedented year for RavenQuest
and our stakeholders. We are excited to take the Company from the
buildout phase to the revenue and profitability phase, and
continuing to accelerate our growth trajectory. There is much to
look forward to for RavenQuest BioMed in 2019.”
For more information, view RavenQuest’s updated
website at www.rqbglobal.com. The BCLDB is responsible for
regulating private retail cannabis licensing and the distribution
of cannabis to retail stores in British Columbia's legal adult-use
recreational cannabis marketplace. The MOU does not represent a
binding purchase agreement, and any distribution of cannabis
products to the BCLDB is subject to the negotiation of such an
agreement on the terms specified by the BCLDB. The Company will
provide additional information regarding the BCLDB supply and
distribution process as it becomes available.
Follow RavenQuest on Twitter
@RQBGlobal
About RavenQuest BioMed
Inc.
RavenQuest BioMed Inc. is a diversified publicly
traded cannabis company with divisions focused upon cannabis
production, management services & consulting and specialized
research & development. RavenQuest is a licensed producer with
facilities located in Markham, Ontario and Edmonton, Alberta.
RavenQuest maintains a research partnership with
McGill University focused upon cultivar (strain) recognition, plant
stabilization and yield maximization of the cannabis plant. The
Company focuses on partnerships with Indigenous communities.
On Behalf of the Board of Directors
ofRAVENQUEST BIOMED INC.
"George Robinson"Chief Executive Officer
For further information, please
contact: |
Mathieu McDonald, Corporate Communications |
|
1-877-282-1586 |
Neither the Canadian Securities Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Canadian Securities Exchange) accepts
responsibility for the adequacy or accuracy of this press release,
which has been prepared by management.
Cautionary Note Regarding
Forward-Looking Statements
All statements in this press release, other than
statements of historical fact, are "forward-looking information"
with respect to the Company within the meaning of applicable
securities laws, including statements with respect to anticipated
production capacity. The Company provides forward-looking
statements for the purpose of conveying information about current
expectations and plans relating to the future and readers are
cautioned that such statements may not be appropriate for other
purposes. By its nature, this information is subject to inherent
risks and uncertainties that may be general or specific and which
give rise to the possibility that expectations, forecasts,
predictions, projections or conclusions will not prove to be
accurate, that assumptions may not be correct and that objectives,
strategic goals and priorities will not be achieved. These risks
and uncertainties include but are not limited to those identified
and reported in the Company’s public filings under the Company’s
SEDAR profile at www.sedar.com. Although the Company has attempted
to identify important factors that could cause actual actions,
events or results to differ materially from those described in
forward-looking information, there may be other factors that cause
actions, events or results not to be as anticipated, estimated or
intended. There can be no assurance that such information will
prove to be accurate as actual results and future events could
differ materially from those anticipated in such statements. The
Company disclaims any intention or obligation to update or revise
any forward-looking information, whether as a result of new
information, future events or otherwise unless required by law.
RavenQuest BioMed (CSE:RQB)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
RavenQuest BioMed (CSE:RQB)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025